Bhat Laxminarayan - 18 Mar 2026 Form 4 Insider Report for REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)

Reporting relationship: President and CEO, Director
Issuer ticker: RVPH
Reported as of: 18 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 Mar 2026, 17:00:20 UTC
Prior SEC filing: 18 Feb 2025
Source filing: View source filing
Reporting owner signature: /s/ Narayan Prabhu, Attorney-in-Fact

Key filing fact

Bhat Laxminarayan filed Form 4 for REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) on 20 Mar 2026.

Key facts

This page summarizes Bhat Laxminarayan's Form 4 filing for REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 20 Mar 2026, 17:00.

Change

Previous filing in this sequence was filed on 18 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001818245 Primary reporting owner

Bhat Laxminarayan

Relationship: President and CEO, Director
Address: C/O REVIVA PHARMACEUTICALS HOLDINGS, INC, 10080 N. WOLFE RD., SUITE SW3-200, CUPERTINO
Signature: /s/ Narayan Prabhu, Attorney-in-Fact
Signature date: 20 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RVPH transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +109,150
Change %
Price: $0.000000^*
Shares after: 109,150
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Common Stock, par value $0.0001 per share
Underlying amount: 109,150
Exercise price: $1.87
Footnotes: F1

RVPH transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +40,925
Change %
Price: $0.000000^*
Shares after: 40,925
Date: 18 Mar 2026
Ownership: By Spouse
Underlying class: Common Stock, par value $0.0001 per share
Underlying amount: 40,925
Exercise price: $1.87
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This option award was made on March 18, 2026 (the "Grant Date") in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). The option provides for vesting as follows: (i) 34,110 of the shares subject to the option are immediately vested on the Grant Date, and (ii) 75,040 shares subject to the option will vest in equal installments on the last day of each month from April 2026 to December 2028. The exercise price is based on the closing price of the Issuer's common stock, par value $0.0001 per share, on the Grant Date in accordance with the terms of the 2020 Plan.

Footnote F2

This option award was made on the Grant Date in accordance with the terms of the Issuer's 2020 Plan. The option provides for vesting as follows: (i) 12,789 of the shares subject to the option are immediately vested on the Grant Date, and (ii) 28,136 shares subject to the option will vest in equal installments on the last day of each month from April 2026 to December 2028. The exercise price is based on the closing price of the Issuer's common stock, par value $0.0001 per share, on the Grant Date in accordance with the terms of the 2020 Plan.